Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Chronic hepatitis B (CHB) remains a significant global health concern.
• Hepatitis B e antigen (HBeAg)-negative CHB treatment aims for sustained biochemical and virological remission.
• Peginterferon alpha-2a and lamivudine are key antiviral therapies for CHB.

Purpose of the Study:

• To evaluate the efficacy of peginterferon alpha-2a with or without lamivudine versus lamivudine monotherapy in HBeAg-negative CHB.
• To identify pre-treatment factors predicting post-treatment response to these therapies.

Main Methods:

• A clinical trial involving 518 patients with HBeAg-negative CHB.
• Multivariate logistic regression analyses were used to assess predictors of response.
• Response was defined as normalized ALT and HBV DNA <20,000 copies/ml at 24 weeks post-treatment.

Main Results:

• Peginterferon alpha-2a (with or without lamivudine) showed higher response rates than lamivudine alone.
• Younger age, female gender, high baseline ALT, low baseline HBV DNA, and specific HBV genotypes (B/C) predicted better response.
• Genotype D patients responded better to combination therapy than peginterferon alpha-2a monotherapy.

Conclusions:

• Pre-treatment factors including baseline ALT, HBV DNA, age, gender, and HBV genotype significantly influence treatment response in CHB.
• HBV genotype is a crucial predictor of sustained response to peginterferon alpha-2a-based therapies at one year post-treatment.